FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1332-1341 September 29, 2005 Number 13 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Parrillo, J. E. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had severe sepsis and a low risk of death.

Methods We randomly assigned adult patients with severe sepsis and a low risk of death (defined by an Acute Physiology and Chronic Health Evaluation [APACHE II] score <25 or single-organ failure) to receive an intravenous infusion of placebo or DrotAA (24 µg per kilogram of body weight per hour) for 96 hours in a double-blind, placebo-controlled, multicenter trial. The prospectively defined primary end point was death from any cause and was assessed 28 days after the start of the infusion. In-hospital mortality within 90 days after the start of the infusion was measured, and safety information was collected.

Results Enrollment in the trial was terminated early because of a low likelihood of meeting the prospectively defined objective of demonstrating a significant reduction in the 28-day mortality rate with the use of DrotAA. The study enrolled 2640 patients and collected data on 2613 (1297 in the placebo group and 1316 in the DrotAA group) at the 28-day follow-up. There were no statistically significant differences between the placebo group and the DrotAA group in 28-day mortality (17.0 percent in the placebo group vs. 18.5 percent in the DrotAA group; P=0.34; relative risk, 1.08; 95 percent confidence interval, 0.92 to 1.28) or in in-hospital mortality (20.5 percent vs. 20.6 percent; P=0.98; relative risk, 1.00; 95 percent confidence interval, 0.86 to 1.16). The rate of serious bleeding was greater in the DrotAA group than in the placebo group during both the infusion (2.4 percent vs. 1.2 percent, P=0.02) and the 28-day study period (3.9 percent vs. 2.2 percent, P=0.01).

Conclusions The absence of a beneficial treatment effect, coupled with an increased incidence of serious bleeding complications, indicates that DrotAA should not be used in patients with severe sepsis who are at low risk for death, such as those with single-organ failure or an APACHE II score less than 25.

Source Information

From the Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver (E.A.); the Department of Critical Care Medicine, St. Luc University Hospital, Université Catholique de Louvain, Brussels (P.-F.L.); Lilly Research Laboratories, Eli Lilly, Indianapolis (R.G., H.L., B.L.T., N.A., B.G.U., W.L.M.); Metro Hospital and Heart Institute, Noida, Uttar Pradesh, India (D.T.); Centre Hospitalier Universitaire de Limoges, Hôpital Dupuytren, Limoges, France (B.F.); Section of Surgical Sciences, Vanderbilt University Medical Center, Nashville (J.S.G.); the First Department of Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany (M.B.); the Adult Intensive Care Unit, Hospital de Clínicas, Universidade Federal do Paraná, Paraná, Brazil (A.R.-N.); Universitätsklinik Aachen, Aachen, Germany (R.R.); Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Tours, France (D.P.); and Klinikum der Medizinischen Fakultät der Martin-Luther-Universität, Halle/Saale, Germany (A.S.).

Address reprint requests to Dr. Abraham at the Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 E. Ninth Ave., Denver, CO 80262, or at edward.abraham{at}UCHSC.edu.

Full Text of this Article

Related Letters:

Drotrecogin Alfa (Activated) in Severe Sepsis
Friedrich J. O., LaRosa S. P., Baillie J.K., Murray G., Abraham E., Laterre P.-F.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:94-96, Jan 5, 2006. Correspondence

This article has been cited by other articles:

• Kellum, J. A., Uchino, S. (2009). International Differences in the Treatment of Sepsis: Are They Justified?. JAMA 301: 2496-2497 [Full Text]  
• Mann, H. J., Short, M. A., Schlichting, D. E. (2009). Protein C in critical illness. Am J Health Syst Pharm 66: 1089-1096 [Abstract] [Full Text]  
• Levitt, J. E., Gould, M. K., Ware, L. B., Matthay, M. A. (2009). Analytic Review: The Pathogenetic and Prognostic Value of Biologic Markers in Acute Lung Injury. J Intensive Care Med 24: 151-167 [Abstract]  
• Elphick, G. F., Sarangi, P. P., Hyun, Y.-M., Hollenbaugh, J. A., Ayala, A., Biffl, W. L., Chung, H.-L., Rezaie, A. R., McGrath, J. L., Topham, D. J., Reichner, J. S., Kim, M. (2009). Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 113: 4078-4085 [Abstract] [Full Text]  
• Schultz, M. J, Dixon, B., Levi, M. (2009). The pulmonary protein C system: preventive or therapeutic target in acute lung injury?. Thorax 64: 95-97 [Full Text]  
• Diaz, L. A., Mortensen, E. M., Anzueto, A., Restrepo, M. I. (2008). Review: Novel targets in the management of pneumonia. Ther Adv Respir Dis 2: 387-400 [Abstract]  
• Eid, A., Wiedermann, C. J., Kinasewitz, G. T. (2008). Early Administration of High-Dose Antithrombin in Severe Sepsis: Single Center Results from the KyberSept-Trial. Anesth. Analg. 107: 1633-1638 [Abstract] [Full Text]  
• Shi, C.-S., Shi, G.-Y., Hsiao, S.-M., Kao, Y.-C., Kuo, K.-L., Ma, C.-Y., Kuo, C.-H., Chang, B.-I., Chang, C.-F., Lin, C.-H., Wong, C.-H., Wu, H.-L. (2008). Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 112: 3661-3670 [Abstract] [Full Text]  
• Clayton, J. K., Starr, J. A. (2008). Novel Approaches to the Treatment of Sepsis Syndrome. Journal of Pharmacy Practice 21: 371-379 [Abstract]  
• Rubenfeld, G. D., Abraham, E. (2008). When Is a Negative Phase II Trial Truly Negative?. Am. J. Respir. Crit. Care Med. 178: 554-555 [Full Text]  
• Liu, K. D., Levitt, J., Zhuo, H., Kallet, R. H., Brady, S., Steingrub, J., Tidswell, M., Siegel, M. D., Soto, G., Peterson, M. W., Chesnutt, M. S., Phillips, C., Weinacker, A., Thompson, B. T., Eisner, M. D., Matthay, M. A. (2008). Randomized Clinical Trial of Activated Protein C for the Treatment of Acute Lung Injury. Am. J. Respir. Crit. Care Med. 178: 618-623 [Abstract] [Full Text]  
• Bland, C. M., Frizzi, J. D., Reyes, A. (2008). Use of Drotrecogin Alfa in Necrotizing Fasciitis: A Case Report and Pharmacologic Review. J Intensive Care Med 23: 342-346 [Abstract]  
• Weitz, J. I., Hirsh, J., Samama, M. M. (2008). New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 234S-256S [Abstract] [Full Text]  
• Pravinkumar, S. E. (2008). Drotrecogin Alfa (Activated): Surviving Sepsis by Chance. Am. J. Respir. Crit. Care Med. 177: 669-669 [Full Text]  
• Ventetuolo, C. E., Levy, M. M. (2008). Sepsis: A Clinical Update. CJASN 3: 571-577 [Full Text]  
• Wheeler, A. P. (2007). Recent Developments in the Diagnosis and Management of Severe Sepsis. Chest 132: 1967-1976 [Abstract] [Full Text]  
• Mosnier, L. O., Yang, X. V., Griffin, J. H. (2007). Activated Protein C Mutant with Minimal Anticoagulant Activity, Normal Cytoprotective Activity, and Preservation of Thrombin Activable Fibrinolysis Inhibitor-dependent Cytoprotective Functions. J. Biol. Chem. 282: 33022-33033 [Abstract] [Full Text]  
• Mackenzie, I., Lever, A. (2007). Management of sepsis. BMJ 335: 929-932 [Full Text]  
• Borgel, D., Bornstain, C., Reitsma, P. H., Lerolle, N., Gandrille, S., Dali-Ali, F., Esmon, C. T., Fagon, J.-Y., Aiach, M., Diehl, J.-L. (2007). A Comparative Study of the Protein C Pathway in Septic and Nonseptic Patients with Organ Failure. Am. J. Respir. Crit. Care Med. 176: 878-885 [Abstract] [Full Text]  
• Levi, M., Levy, M., Williams, M. D., Douglas, I., Artigas, A., Antonelli, M., Wyncoll, D., Janes, J., Booth, F. V., Wang, D., Sundin, D. P., Macias, W. L., for the Xigris and Prophylactic HepaRin Evaluation, (2007). Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated). Am. J. Respir. Crit. Care Med. 176: 483-490 [Abstract] [Full Text]  
• Higgins, T. L. (2007). Quantifying Risk and Benchmarking Performance in the Adult Intensive Care Unit. J Intensive Care Med 22: 141-156 [Abstract]  
• Sauermann, R., Marsik, C., Steiner, I., Seir, K., Cvitko, T., Zeitlinger, M., Wagner, O., Joukhadar, C. (2007). Immunomodulatory Effects of Fosfomycin in Experimental Human Endotoxemia. Antimicrob. Agents Chemother. 51: 1879-1881 [Abstract] [Full Text]  
• Remick, D. G. (2007). Pathophysiology of Sepsis. Am. J. Pathol. 170: 1435-1444 [Abstract] [Full Text]  
• Mosnier, L. O., Zlokovic, B. V., Griffin, J. H. (2007). The cytoprotective protein C pathway. Blood 109: 3161-3172 [Abstract] [Full Text]  
• Gruber, A., Marzec, U. M., Bush, L., Di Cera, E., Fernandez, J. A., Berny, M. A., Tucker, E. I., McCarty, O. J. T., Griffin, J. H., Hanson, S. R. (2007). Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood 109: 3733-3740 [Abstract] [Full Text]  
• Perel, A., Segal, E., Khurana, A., Vinayek, N., Mackenzie, A. F., Bartelink, A. K.M., Van Cromphaut, S., Wilmer, A., Van den Berghe, G., Russell, J. A. (2007). Management of Sepsis. NEJM 356: 1178-1182 [Full Text]  
• Watson, H. G, Greaves, M. (2007). Review: New anticoagulants: a story of promise and disappointment. British Journal of Diabetes & Vascular Disease 7: 51-58 [Abstract]  
• Zeitlinger, M., Marsik, C., Steiner, I., Sauermann, R., Seir, K., Jilma, B., Wagner, O., Joukhadar, C. (2007). Immunomodulatory effects of fosfomycin in an endotoxin model in human blood. J Antimicrob Chemother 59: 219-223 [Abstract] [Full Text]  
• Moss, M. (2006). Clinical Year in Review III: Critical Care, Mechanical Ventilation, Sleep Medicine, and Lung Cancer. Proc Am Thorac Soc 3: 645-649 [Full Text]  
• Otero, R. M., Nguyen, H. B., Huang, D. T., Gaieski, D. F., Goyal, M., Gunnerson, K. J., Trzeciak, S., Sherwin, R., Holthaus, C. V., Osborn, T., Rivers, E. P. (2006). Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings.. Chest 130: 1579-1595 [Abstract] [Full Text]  
• Russell, J. A. (2006). Management of Sepsis. NEJM 355: 1699-1713 [Full Text]  
• Feistritzer, C., Schuepbach, R. A., Mosnier, L. O., Bush, L. A., Di Cera, E., Griffin, J. H., Riewald, M. (2006). Protective Signaling by Activated Protein C Is Mechanistically Linked to Protein C Activation on Endothelial Cells. J. Biol. Chem. 281: 20077-20084 [Abstract] [Full Text]  
• Dombrovskiy, V., Martin, A., Sunderram, J., Paz, H. (2006). Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals.. Am J Health Syst Pharm 63: 1151-1156 [Abstract] [Full Text]  
• Maeder, M., Fehr, T., Rickli, H., Ammann, P. (2006). Sepsis-Associated Myocardial Dysfunction: Diagnostic and Prognostic Impact of Cardiac Troponins and Natriuretic Peptides. Chest 129: 1349-1366 [Abstract] [Full Text]  
• Milbrandt, E. B., Ishizaka, A., Angus, D. C. (2006). Update in critical care 2005.. Am. J. Respir. Crit. Care Med. 173: 833-841 [Full Text]  
• (2006). ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB. Evid. Based Med. 11: 62-62 [Full Text]  
• Fowler, R. A., Annane, D. (2006). The Highs and Lows of Intensive Insulin Therapy. Am. J. Respir. Crit. Care Med. 173: 367-369 [Full Text]  
• Vincent, J.-L., Abraham, E. (2006). The Last 100 Years of Sepsis. Am. J. Respir. Crit. Care Med. 173: 256-263 [Abstract] [Full Text]  
• Friedrich, J. O., LaRosa, S. P., Baillie, J.K., Murray, G., Abraham, E., Laterre, P.-F. (2006). Drotrecogin Alfa (Activated) in Severe Sepsis. NEJM 354: 94-96 [Full Text]  
• (2006). {blacktriangledown}Drotrecogin alfa (activated) for severe sepsis. DTB 44: 5-8 [Abstract] [Full Text]  
• Harrison, L. H. (2006). Prospects for Vaccine Prevention of Meningococcal Infection. Clin. Microbiol. Rev. 19: 142-164 [Abstract] [Full Text]  
• Rivers, E. P., McIntyre, L., Morro, D. C., Rivers, K. K. (2005). Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ 173: 1054-1065 [Abstract] [Full Text]  
• (2005). Drotrecogin Alfa Not Beneficial for Patients with Severe Sepsis at Low Risk for Death. JWatch Infect. Diseases 2005: 2-2 [Full Text]  
• Tonks, A. (2005). What's new in the other general journals. BMJ 331: 801-802 [Full Text]  
• (2005). Xigris Ineffective in Low-Risk Patients with Severe Sepsis. JWatch General 2005: 2-2 [Full Text]  
• Parrillo, J. E. (2005). Severe sepsis and therapy with activated protein C.. NEJM 353: 1398-1400 [Full Text]